Health ❯ Diabetes

Type 2 Diabetes

Treatment Options Medications Risk Factors Medication Management GLP-1 Receptor Agonists Complications Prediabetes Treatment Obesity

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

The warning focuses on mass-marketed 'personalized' versions sold outside FDA review.

GLP-1 Drugs Tied to Lower Addiction Risk and Harms in Large VA Study

GLP-1 Drugs Tied to Lower Addiction Risk and Fewer Severe Outcomes in Major BMJ Analysis

Brazil Nears Semaglutide Patent Expiry as Anvisa Reviews 14 Filings and Novo Nordisk Counters

GLP-1 Drugs Plus Healthy Habits Linked to Lower Heart Risk in Large VA Diabetes Study

Study Finds Waist-to-Height Ratio Outperforms BMI for Flagging Diabetes Risk in U.S. Youth

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

NHS Starts Targeted Mounjaro Prescribing as Norfolk–Waveney ICB Estimates Over 11,000 Eligible

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

After-Meal Blood Sugar Spikes Tied to 69% Higher Alzheimer’s Risk, Large Genetic Study Finds

Oxford Review Finds Rapid Weight Regain After Stopping GLP-1 Drugs

Daylight Exposure Improves Glucose Stability in Controlled Type 2 Diabetes Trial

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Brazil Cracks Down on Illicit Mounjaro Sales as Lilly Launches QR Verification Tool

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Gut Microbe Molecule TMA Inhibits IRAK4, Easing Diet-Driven Inflammation in Diabetes Models

Mexico's Diabetes Crisis Widens as Costs Climb and Vision Risks Mount